Education
About Us
Working with TipRanks
Follow Us
SenesTech Inc (SNES)
NASDAQ:SNES
Top Page
SenesTech
(NASDAQ:SNES)
Rating:57Neutral
Price Target:
$6.00
▲(6.38%Upside)
SenesTech (SNES) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$19.72M
Dividend YieldN/A
Average Volume (3M)256.10K
Price to Earnings (P/E)―
Beta (1Y)1.36
Revenue Growth40.15%
EPS Growth94.78%
CountryUS
Employees23
SectorBasic Materials
Sector Strength67
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)-1.28
Shares Outstanding3,506,399
10 Day Avg. Volume171,538
30 Day Avg. Volume256,097
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)2.11
Price to Sales (P/S)0.00
P/FCF Ratio-1.80
Enterprise Value/Market Cap0.46
Enterprise Value/Revenue1.31
Enterprise Value/Gross Profit7.75
Enterprise Value/Ebitda-0.36
Forecast
1Y Price Target
$4.50Price Target Upside-20.21% Downside
Rating ConsensusHold
Number of Analyst Covering0
SenesTech Business Overview & Revenue Model
Company DescriptionSenesTech, Inc. is a biotechnology company that specializes in the development and commercialization of innovative pest control solutions. The company operates in the agricultural and pest management sectors, focusing primarily on non-lethal management of animal populations through fertility control. SenesTech's flagship product, ContraPest, is a rodent fertility control bait designed to reduce rat populations humanely and sustainably. This product is aimed at a variety of markets including urban centers, agricultural settings, and conservation areas.
How the Company Makes MoneySenesTech generates revenue primarily through the sale of its proprietary product, ContraPest, which is distributed to pest management professionals, agricultural businesses, and municipalities. The company's revenue model is based on the direct sale and distribution of this product, which offers a unique, humane, and sustainable solution for rodent population control. SenesTech's earnings are significantly influenced by its ability to expand market penetration and adoption of ContraPest among key industries and regions. Additionally, partnerships with pest control operators and distributors enhance the company's market reach and contribute to its revenue streams.
SenesTech Earnings Call Summary
Earnings Call Date:May 08, 2025
(Q1-2025)
| % Change Since: 125.60%|
Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment Positive
The company showed strong growth in its Evolve product line and significant progress in municipal and international markets, with improved gross margins and operational efficiencies. However, challenges remain in brick and mortar retail expansion and international sales recognition.Q1-2025 Updates
Positive Updates
Evolve Product Line Expansion
Evolve revenue grew 40% compared to the previous year, with gross margins increasing to nearly 65%, up from 33%, resulting in a 132% increase in gross profit.
Municipal and Ecommerce Growth
Significant deployments in major U.S. cities like Chicago and New York. Ecommerce sales increased by 107% over the last year.
International Market Expansion
Agreements signed for distribution in 12 countries, with commercial shipments occurring in Hong Kong, UAE, Maldives, and Netherlands.
Operational Efficiency Improvements
Implemented initiatives to reduce expenses by $2 million annually, lowering the revenue threshold for cash flow breakeven to $1.5 million quarterly.
Record Gross Profit
Gross profit for the first quarter was the highest in the company's history due to the launch of Evolve.
Negative Updates
Brick and Mortar Retail Challenges
Limited progress in achieving shelf space in brick and mortar retail, with growth primarily dependent on ecommerce performance.
No Recognized International Sales in Q1
Awaiting follow-on orders from international markets, with no recognized international sales during Q1.
Company Guidance
During the SenesTech First Quarter Fiscal Year 2025 Financial Results Conference Call, the company reported significant progress with its Evolve product line, which now accounts for 79% of first-quarter sales and has driven a 40% increase in revenue compared to the same period last year. Evolve's success has led to gross margins rising to a record 65%, up from 33% the previous year, contributing to a 132% increase in gross profit dollars. The company has expanded its presence through ecommerce, municipal deployments, and international markets, with ecommerce sales up 107% year-over-year, now making up 61% of their total sales. Municipal sales have seen a sevenfold increase, with deployments in major U.S. cities like Chicago and New York. The company has also signed distribution agreements in 12 countries and territories, with shipments planned for markets including Australia and New Zealand. Operational optimizations have reduced the cash flow breakeven threshold to $1.5 million in quarterly revenue, down from $12 million annually. Despite challenges in brick-and-mortar retail, SenesTech's focus on high-margin Evolve products and cost-reduction initiatives positions it for future growth and profitability.SenesTech Financial Statement Overview
Summary
SenesTech's financial performance reflects potential with revenue growth and a stable balance sheet, but faces profitability challenges with ongoing net losses and negative cash flows. The improvement in gross profit margin is positive, yet the inability to achieve positive net income and cash flows limits the score.Income Statement
SenesTech has shown some revenue growth, with a significant increase from $1,193,000 in 2023 to $1,857,000 in 2024. However, the company is still struggling with profitability, as evidenced by the negative EBIT and net income. The gross profit margin has improved, but the net profit margin remains non-existent due to zero net income in 2024. These factors result in a moderate score, reflecting positive revenue trends but ongoing profitability challenges.45
Neutral
Balance Sheet
The balance sheet indicates a stable equity position with a decrease in total liabilities over the years. The debt-to-equity ratio is low, showing conservative leverage. However, the return on equity is weak due to persistent net losses, limiting the score to an average level. The company's financial stability is supported by a solid equity base, but profitability issues weigh heavily.50
Neutral
Cash Flow
SenesTech's cash flow statement reveals challenges with negative operating and free cash flows, despite some improvement in free cash flow from 2023 to 2024. The operating cash flow to net income ratio cannot be calculated for 2024 due to zero net income. The company has relied on financing activities to manage cash needs, reflecting ongoing cash flow struggles and reducing the score.40
Negative
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.86M | 1.19M | 1.02M | 576.00K | 258.00K |
| Gross Profit | 1.00M | 539.00K | 464.00K | 220.00K | -23.00K |
| EBITDA | -6.01M | -7.57M | -9.51M | -7.95M | -7.62M |
| Net Income | -6.18M | -7.71M | -9.71M | -7.98M | -7.70M |
Balance Sheet | |||||
| Total Assets | 3.28M | 7.29M | 6.78M | 11.50M | 6.02M |
| Cash, Cash Equivalents and Short-Term Investments | 1.31M | 5.39M | 4.78M | 9.33M | 3.64M |
| Total Debt | 262.00K | 406.00K | 359.00K | 555.00K | 1.44M |
| Total Liabilities | 767.00K | 942.00K | 1.50M | 1.47M | 2.14M |
| Stockholders Equity | 2.51M | 6.35M | 5.28M | 10.04M | 3.88M |
Cash Flow | |||||
| Free Cash Flow | -6.12M | -7.71M | -8.75M | -7.88M | -7.22M |
| Operating Cash Flow | -6.03M | -7.57M | -8.58M | -7.78M | -7.11M |
| Investing Cash Flow | -56.00K | -149.00K | -170.00K | -99.00K | -67.00K |
| Financing Cash Flow | 2.00M | 8.34M | 4.20M | 13.56M | 8.88M |
SenesTech Technical Analysis
Positive
5.64
Price Trends
3.87
Positive
3.02
Positive
2.94
Positive
Market Momentum
0.44
Negative
67.64
Neutral
82.34
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNES, the sentiment is Positive. The current price of 5.64 is above the 20-day moving average (MA) of 5.05, above the 50-day MA of 3.87, and above the 200-day MA of 2.94, indicating a bullish trend. The MACD of 0.44 indicates Negative momentum. The RSI at 67.64 is Neutral, neither overbought nor oversold. The STOCH value of 82.34 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SNES.
SenesTech Risk Analysis
SenesTech disclosed 33 risk factors in its most recent earnings report. SenesTech reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
SenesTech Peers Comparison
Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Performance Comparison
SNES
SenesTech
5.64
0.45
8.67%
ITP
IT Tech Packaging
0.21
-0.03
-12.50%
BHILQ
Benson Hill
0.01
-6.55
-99.85%
SenesTech Corporate Events
Executive/Board Changes
SenesTech Appoints Lynn Y. Graham to Board
Neutral
Jul 10, 2025
On July 5, 2025, SenesTech‘s Board of Directors expanded to seven members, appointing Lynn Y. Graham as an independent Class III director until the 2028 Annual Meeting of Stockholders. Ms. Graham will also join the Board’s Commercialization Committee, with no prior arrangements influencing her selection and no related transactions under Regulation S-K.
The most recent analyst rating on (SNES) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on SenesTech stock, see the SNES Stock Forecast page.
Private Placements and Financing
SenesTech Raises $4.4M Through Warrant Exercise
Neutral
Jul 1, 2025
On June 30, 2025, SenesTech entered into agreements with certain warrant holders for the exercise of existing warrants to purchase 1,458,872 shares of common stock at $2.90 per share, generating gross proceeds of approximately $4.4 million. In exchange, SenesTech will issue new short-term warrants for the same number of shares at an exercise price of $4.15 per share, with potential additional proceeds of $6.0 million if fully exercised. The company plans to use the funds for working capital and general corporate purposes, with H.C. Wainwright acting as the exclusive placement agent for the transaction.
The most recent analyst rating on (SNES) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on SenesTech stock, see the SNES Stock Forecast page.
Private Placements and Financing
SenesTech Registers Additional Shares for Capital Raising
Neutral
Jun 30, 2025
On June 30, 2025, SenesTech registered an additional $711,227 worth of common stock shares under its At The Market Offering Agreement with H.C. Wainwright & Co., LLC. Prior to this, the company had sold $2,854,827.84 in shares through the same agreement, indicating ongoing efforts to raise capital.
The most recent analyst rating on (SNES) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on SenesTech stock, see the SNES Stock Forecast page.
Delistings and Listing ChangesExecutive/Board ChangesShareholder MeetingsStock Split
SenesTech Stockholders Approve Key Proposals at Annual Meeting
Neutral
Jun 10, 2025
On June 9, 2025, SenesTech held its Annual Meeting in Surprise, Arizona, where stockholders voted on several key proposals. The election of Class III directors, approval of executive compensation for fiscal 2024, ratification of M&K CPAS, PLLC as the accounting firm, and authorization of common stock issuance were among the approved items. However, the amendment to increase shares under the 2018 Plan was not approved. Additionally, stockholders approved a reverse stock split proposal to maintain Nasdaq listing and an adjournment proposal to allow further voting if necessary.
The most recent analyst rating on (SNES) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on SenesTech stock, see the SNES Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.